Jiangsu Recbio Technology Co., Ltd. (HKG:2179)
Hong Kong · Delayed Price · Currency is HKD 4.080
0.00 (0.00%)
At close: Mar 27, 2026
Jiangsu Recbio Technology Revenue
In the year 2025, Jiangsu Recbio Technology had annual revenue of 12.73M CNY, down -52.88%. Jiangsu Recbio Technology had revenue of 19.73M in the half year ending June 30, 2025, with 329.17% growth.
Revenue
12.73M CNY
Revenue Growth
-52.88%
P/S Ratio
177.71
Revenue / Employee
25.10K CNY
Employees
507
Market Cap
2.52B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 12.73M | -14.28M | -52.88% |
| Dec 31, 2024 | 27.01M | -3.37M | -11.10% |
| Dec 31, 2023 | 30.38M | 25.05M | 470.46% |
| Dec 31, 2022 | 5.33M | -874.00K | -14.10% |
| Dec 31, 2021 | 6.20M | 4.74M | 325.17% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Frontage Holdings | 1.99B |
| Hangzhou Jiuyuan Genetic Biopharmaceutical | 1.43B |
| AIM Vaccine | 1.38B |
| Mabpharm | 718.98M |
| Medtide | 546.29M |
| Cutia Therapeutics | 374.07M |
| ImmuneOnco Biopharmaceuticals (Shanghai) | 171.70M |
| Antengene Corporation | 117.22M |